White Birch Allergy Shots (SCIT)
White birch (Betula pendula) is the only Fagales species with Phase 3 RCT evidence at both adult and pediatric levels β the Itulazax TT-04 trial in 634 adults and a pediatric Phase 3 in 952 children. Despite this, Itulazax is not FDA-approved in the US, so American patients access equivalent Bet v 1 immunotherapy via non-standardized SCIT injections or off-label sublingual drops.
About Curexβs SCIT program
Curexβs at-home allergy shots (SCIT) are coming soon and focus on the most common environmental allergens:
- β’ Pollens β tree, grass, weed & ragweed
- β’ Pet dander β cat & dog
- β’ Dust mites
- β’ Molds β Alternaria & mold mix
White Birchis covered here for general education and may not be part of Curexβs current treatment set. Join the waitlist and our care team will help confirm your options.
White Birch Allergy Immunotherapy: How It Works
Allergy immunotherapy is the only long-term treatment that re-trains the immune system to stop overreacting to white birch β rather than just masking symptoms with antihistamines or steroids. By gradually exposing the body to controlled doses of white birch allergen, immunotherapy shifts the underlying allergic response and produces relief that often outlasts treatment by 7β10 years.
There are two evidence-based forms of white birch immunotherapy used today, both built on the same desensitization principle but delivered very differently.
of sustained relief after a complete immunotherapy course β the only allergy treatment with proven long-term effect after stopping.
Allergy Shots (SCIT)
Weekly injections of white birch extract in a clinic, escalating over 3β6 months until a maintenance dose is reached. Continued monthly for 3β5 years. Longest clinical track record for white birch allergy.
- Strongest evidence base for severe and polysensitized patients
- Covered by most insurance plans
- Requires 50β100+ in-person clinic visits across the full course
- Or at home with no clinic visitsβ Curexβs Virtual Shot Room model delivers the same SCIT program with live video supervision by trained Curex clinical staff for the first injection from each new vial or concentration and restarts after gaps or reactions.
Allergy Drops / Tablets (SLIT)
Daily drops or dissolvable tablets containing white birch extract, held under the tongue at home. Same desensitization principle, delivered without injections. WHO-recognized as an effective form of allergy immunotherapy since 2001.
- Taken at home β no weekly clinic trips, no needles
- Lower systemic reaction rate than allergy shots
- Curex offers prescription white birch immunotherapy drops with allergist oversight
The rest of this page goes deep on allergen-specific immunotherapy with shots β protocol, efficacy data, side effects, and cost. If youβd rather skip the clinic and treat white birch allergy with at-home drops, see how Curex sublingual immunotherapy compares below.
What is White Birch?
The biology, taxonomy, and clinical fingerprint of White Birch β the foundation of how SCIT targets it.
Betula pendula β silver birch β produces pollen in long pendulous catkins from late March through May; aerial concentrations regularly reach several thousand grains per cubic meter at peak season across New England and the Upper Midwest.
- Scientific name
- Betula pendula Roth (synonym B. verrucosa)
- Family
- BetulaceaeBirch family
- Type
- Deciduous tree pollen
- Native to
- Northern and central Europe; widely naturalized across the northern US tier
- Allergen proteins
- Bet v 1 (major) β PR-10, 17.5 kDa, up to 95% IgE reactivity (Moverare 2002); ~30 isoforms; founder of PR-10 superfamilyBet v 2 β Profilin, 14β15 kDa, pan-allergen marker, ~10β20% reactivityBet v 3 β Polcalcin, 24 kDa, 4-EF-handBet v 4 β Polcalcin, 9 kDa, 2-EF-handBet v 6 β Isoflavone reductase, 33 kDaBet v 7 β Cyclophilin, 18 kDa
- Particle size
- 20β24 ΞΌm
- Avoidance difficulty
- Nearly impossible
How White Birch Allergy Presents
Symptoms by body system β useful for distinguishing White Birch sensitivity from overlapping allergies and infections.
Respiratory
- Moderate-to-severe sneezing and rhinorrhea during the AprilβMay peak
- Nasal congestion that worsens on high-count days, often exceeding 1,000 grains/mΒ³
- Itchy nasal passages with post-nasal drip and chronic cough
- Allergic asthma exacerbations β wheezing and chest tightness in susceptible patients
- Eustachian tube dysfunction causing ear pressure and hearing changes during peak weeks
Ocular
- Intense bilateral eye itching and watering β a hallmark of birch sensitization
- Conjunctival redness and swelling (allergic conjunctivitis)
- Morning eye crusting from overnight allergen accumulation
- Photophobia and reduced visual comfort on high-pollen days
Dermal
- Oral allergy syndrome (OAS) β lip tingling and throat itch after eating raw apple, hazelnut, peach, cherry, carrot, or celery (Bet v 1 PR-10 cross-reactivity; heat-labile, cooked forms usually tolerated)
- Contact urticaria in highly sensitized patients from direct pollen contact
- Periorbital eczema flares coinciding with peak birch-season pollen counts
Systemic
- Severe fatigue during the 4β6-week birch season β a common complaint in the Upper Midwest and New England
- Sleep disturbance from nighttime nasal obstruction leading to daytime impairment
- Anxiety and dietary restriction from uncertain OAS food triggers
- Quality-of-life impairment comparable to major medical conditions during peak weeks (Anderegg 2021 PNAS β seasons are lengthening)
White birch is the only tree pollen where I can cite a Phase 3 trial in 634 adults and a separate Phase 3 in 952 children β the Itulazax TT-04 program. The catch for US patients is that the SLIT tablet isn't FDA-approved here, so we deliver the same Bet v 1 immunotherapy by injection. Component-resolved testing first β Bet v 1 versus Bet v 2 β tells me whether immunotherapy will work, and for eligible patients that injection course can now be self-administered at home with Curex, with the first injection from each new vial or concentration supervised live in the Virtual Shot Room.
When & Where White Birch Peaks
Allergen intensity by month and by state. Useful for timing SCIT start dates and travel planning.
12-Month Intensity
Peak: late April through mid-May across the northern US; FebruaryβApril in the southeastern rangeΒ· ~6β8 weeks of clinically significant airborne pollen; climate change has pushed season start ~8 days earlier since 1990 (Anderegg 2021 PNAS)
US Exposure Map
15 high-intensity statesExposure intensity by state (text version)
- ME:
- High
- VT:
- High
- NH:
- High
- WA:
- High
- MT:
- Moderate
- ND:
- Moderate
- MN:
- High
- WI:
- High
- MI:
- High
- NY:
- High
- MA:
- High
- OR:
- High
- ID:
- Moderate
- WY:
- Moderate
- SD:
- Moderate
- IA:
- Moderate
- IL:
- Moderate
- IN:
- Moderate
- OH:
- High
- PA:
- High
- NJ:
- High
- CT:
- High
- RI:
- High
- CA:
- Moderate
- NV:
- Low
- UT:
- Low
- CO:
- Moderate
- NE:
- Low
- MO:
- Moderate
- KY:
- Low
- WV:
- Moderate
- VA:
- Moderate
- MD:
- Moderate
- DE:
- Moderate
- AZ:
- Low
- NM:
- Low
- KS:
- Low
- AR:
- Low
- TN:
- Low
- NC:
- Low
- SC:
- Low
- OK:
- Low
- LA:
- Low
- MS:
- Low
- AL:
- Low
- GA:
- Low
- TX:
- Low
- FL:
- Low
- AK:
- Low
- HI:
- Low
What White Birch Cross-Reacts With
Patients sensitized to one allergen often react to others sharing similar proteins. This map shows the documented molecular overlaps.
White birch's Bet v 1 is the founding member of the PR-10 protein superfamily β it cross-reacts with 12+ Fagales tree pollens and more than 20 fresh foods, making oral allergy syndrome virtually universal in birch-sensitized patients. The cross-reactivity follows sequence identity, ranging from 88% with alder to 66% with beech.
Aln g 1 β 88% amino-acid identity with Bet v 1 (Strobl & Lehmann 2024); r=0.994 IgE correlation (Choi 2019)
Que a 1 72β95% identity; 77.4β81.5% Bet v 1 IgE inhibition by white oak extract (Jeong 2016)
Mal d 1 β canonical PR-10 OAS trigger; heat-labile
Cor a 1.04 β heat-labile PR-10 OAS; distinct from anaphylactic Cor a 8/9/14
Jug r 5 β 94% of birch-allergic walnut-allergic patients react (Wangorsch 2017); heat-labile
BirchβAppleβHazelnut (Bet v 1 PR-10) Oral Allergy Syndrome
Bet v 1 is the structural template for PR-10 proteins expressed in dozens of raw fruits, tree nuts, and vegetables. Birch-sensitized patients with high IgE to Bet v 1 frequently develop tingling, lip swelling, or throat itch when eating raw forms of these foods β symptoms that disappear when the food is cooked or canned because PR-10 proteins denature with heat. This is distinct from anaphylactic food allergy driven by heat-stable storage proteins. A board-certified allergist can separate PR-10 OAS (manageable) from storage-protein anaphylaxis risk (requires strict avoidance + epinephrine carry) via component-resolved testing.
Is SCIT Right for Your White Birch Allergy?
Answer five questions to get a personalized assessment of whether white birch SCIT is likely right for you.
How severe are your spring birch-season symptoms (AprilβMay)?
The White Birch SCIT Protocol
White birch SCIT uses non-standardized B. pendula (or B. verrucosa) extract in a conventional ladder protocol. No US tree pollen extract is FDA-standardized; the Itulazax SLIT-tablet is not FDA-approved in the US as of May 2026, making conventional SCIT injections the primary vehicle for Bet v 1 immunotherapy in American patients.
Injections begin at 1:100,000 w/v and increase incrementally at each visit, guided by local skin reactions β Curex starts at a more conservative 1:100,000 dilution than the textbook 1:10,000 default. Patients with active PR-10 OAS (especially to raw apple, hazelnut, or peach) may have elevated build-up reactivity and may benefit from a slower up-dosing protocol. Traditionally each injection was followed by a 30-minute observation period in the clinic; with Curex, eligible patients self-administer the same escalation schedule at home, and the first injection from each new vial or concentration is supervised live in the Virtual Shot Room with a prescribed epinephrine auto-injector confirmed on hand.
Ongoing maintenance injections at the target dose sustain long-term Bet v 1 tolerance. Most patients notice clinically meaningful improvement by the second birch season. The Itulazax TT-04 family-level evidence confirms this immunologic target β Bet v 1 at 12 SQ-Bet equivalent dose β produces durable symptom reduction across the entire birch-homologous Fagales group.
Patients who complete the full 3β5 year course may experience lasting benefit for 7β12+ years after stopping. Discontinuation after fewer than 3 years is associated with higher relapse rates. Your allergist will evaluate symptom scores and sensitization levels before recommending whether to stop or extend.
Extract Concentration Ladder
You progress through each vial during build-up. Concentration increases ~10x per step.
What the Research Shows for White Birch SCIT
White birch SCIT has the strongest evidence base of any tree-pollen allergen β anchored by two conventional SCIT RCTs and the landmark Itulazax TT-04 Phase 3 trial. All evidence should be interpreted in the context of non-standardized US extract variability and the fact that the SLIT-tablet trials (Itulazax) were conducted in Europe with a standardized 12 SQ-Bet dose.
- Combined symptom-medication score reduction68%
- Rhinoconjunctivitis symptom score reduction (SCIT RCT)65%Bodtger U et al., Allergy 2002; Arvidsson MB et al., Allergy 2002 (conventional aqueous SCIT)
- Pediatric symptom-medication score improvement60%ALK pediatric Phase 3, N=952 children β EU pediatric extension 2025 (SLIT-tablet)
No conventional SCIT RCT for white birch has been conducted in the US at the scale of Itulazax TT-04; US practice extrapolates from European SCIT RCTs (Bodtger 2002, Arvidsson 2002) and the family-level Itulazax Phase 3 program. The molecular basis for efficacy β Bet v 1 desensitization β is identical whether immunotherapy is delivered by injection or SLIT tablet, providing a strong immunologic rationale for US SCIT practice even in the absence of a US-specific Phase 3 trial.
Ready to skip the surprise bills?
At-home allergy shots (SCIT) are designed by board-certified allergists. See the listed SCIT plan rate in our pricing record and request a quote for eligibility, initiation and total care costs.
- MD-ledBoard-certified allergists
- QuoteTotal care estimate
- 50K+Patients treated
- HSA/FSAEligible
White Birch SCIT Side Effects
White birch SCIT side effects follow the standard inhalant SCIT profile with one additional consideration: patients with active PR-10 OAS (raw apple, hazelnut, peach reactions) are more likely to experience build-up reactions, and slower up-dosing should be discussed with your allergist.
Local reactions
4 documented| Reaction | Rate | Severity |
|---|---|---|
Injection-site swelling Expected during build-up; peaks at 1β2 hours and resolves within 24 hours in most cases | Rate 30β50% | Mild |
Injection-site itching Ice application and pre-treatment antihistamine are commonly recommended | Rate 20β40% | Mild |
Large local reaction (>25 mm) More frequent in PR-10 OAS patients; does not reliably predict systemic risk | Rate 5β10% per injection during build-up | Moderate |
Persistent warmth and redness Typically resolves within 24 hours | Rate 10β20% | Mild |
Systemic reactions
4 documented| Reaction | Rate | Severity |
|---|---|---|
Rhinitis/conjunctivitis flare Sneezing or watery eyes within minutes to 1 hour of injection; antihistamine responsive | Rate 0.5β1% | Mild |
Urticaria Generalized hives; managed with antihistamines and epinephrine if progressive | Rate 0.1β0.5% | Moderate |
Bronchospasm Asthmatic patients have elevated risk; active asthma must be controlled before initiating SCIT | Rate 0.1β0.3% | Moderate |
Anaphylaxis Rare at properly titrated doses; the prescribing physician supervises the first injection from each new vial or concentration live in the Virtual Shot Room and confirms a prescribed epinephrine auto-injector is on hand, with onset typically within 30 minutes. | Rate <0.01% | Severe |
A 30-minute post-injection observation accompanies every birch SCIT dose, whether given in a clinic or self-administered at home with Curex β where the first injection from each new vial or concentration is supervised live in the Virtual Shot Room by trained Curex clinical staff. Patients with Bet v 1-driven food OAS should notify their allergist about any recent food reactions or PR-10 food introductions, as these clinical signals can affect up-dosing decisions.
SCIT vs Alternatives for White Birch
White birch-allergic patients have four primary treatment pathways: allergy shots (SCIT) β now available as a weekly at-home injection with Curex β sublingual drops, avoidance measures, and daily medications. The strongest immunotherapy evidence for this allergen, the Itulazax TT-04 program, was a SLIT-tablet trial, but that specific product is not available in the US.
| Criterion | SCITBest | SLIT | Avoidance | Medications |
|---|---|---|---|---|
| Effectiveness | High β two conventional SCIT RCTs; family-level Phase 3 (Itulazax TT-04, 634 adults) | High for Bet v 1 SLIT-tablet (Itulazax TT-04, EU only); off-label drops in US are standard extract | Low β birch pollen counts reach thousands of grains/mΒ³; essentially unavoidable at peak | Moderate β antihistamines + intranasal corticosteroids for mild-moderate symptoms |
| 5-yr cost | $3,500β$15,000 over 5 years | Varies by provider; sold as a general sublingual modality, not Curex's product | Low β HEPA, pollen masks, air purifiers | $500β$2,000 over 5 years |
| Duration | 3β5 year course | 3β5 year course | Indefinite β no tolerance change | Indefinite β seasonal use every year |
| Convenience | At-home weekly self-injection with Curex (3β6 months build-up, then monthly); the first injection from each new vial or concentration supervised live in the Virtual Shot Room | Daily at-home β no clinic required | Moderate inconvenience AprilβMay | High convenience |
| Safety | Excellent β birch serum is USP <797> sterile-compounded, the first injection from each new vial or concentration is supervised live in the Virtual Shot Room, a prescribed epinephrine auto-injector is confirmed on hand, and you self-observe 30 minutes | Favorable; no systemic anaphylaxis in Itulazax trials | Safe | Generally safe |
| Lasting effect | 7β12+ years after completion | Emerging β less durability data vs SCIT | None β symptoms return each season | None β must take every season |
SCITBest
SLIT
Avoidance
Medications
SCIT delivers the same Bet v 1 immunotherapy studied in the Itulazax TT-04 Phase 3 program β and with Curex eligible patients self-administer that weekly shot at home with pricing confirmed in a current program quote, with the first injection from each new vial or concentration supervised live in the Virtual Shot Room and a prescribed epinephrine auto-injector confirmed on hand. It remains the option with the deepest durability evidence for lasting birch relief.
What White Birch SCIT Actually Costs
Most major US insurers cover birch SCIT under standard allergy immunotherapy benefits when prescribed by a board-certified allergist with supporting skin-prick test or specific IgE (including Bet v 1 component testing). Out-of-pocket cost varies by deductible, co-insurance, and whether extract preparation and injection services are billed separately. Curex at-home IgE testing identifies specific white birch sensitization before allergist consultations, eliminating the need for an initial skin-test visit.
Cost range varies by deductible, co-insurance, and clinic.
Verify these codes with your insurer to confirm coverage.
See the listed Environmental Allergy Shots Plan rate, commercial terms dated 2026-10-12; consultations are included without copay. Confirm availability, eligibility, other included services, testing, any in-person care, insurance responsibility and billing cadence in your written quote before enrolling.
Join the waitlistStop guessing about your white birch allergy. Get a plan.
Take Curexβs 3-minute allergy quiz. A board-certified allergist will review your symptoms and recommend the right immunotherapy path for you β shots or drops.
Free quiz Β· Board-certified allergists Β· 50,000+ patients treated Β· HSA/FSA eligible
White Birch SCIT β Frequently Asked
Quick answers to the questions patients ask most before starting treatment.
Itulazax (ALK-AbellΓ³) received EMA approval in Europe in 2019 and is approved in 22+ countries plus Canada, but the manufacturer has not sought FDA approval. Per GlobalData analyst commentary reported by BioSpace in February 2020, this is because SLIT tablets have seen 'mediocre uptake' in the US compared with Europe β US patients and insurers have historically preferred SCIT injections, making it commercially unattractive to run a separate US Phase 3 program. As a result, US patients with white birch allergy access Bet v 1 immunotherapy through non-standardized SCIT extracts (the injection route) or off-label sublingual drops, neither of which has the same regulatory approval status as Itulazax in Europe.
Bet v 1 is a 17.5 kDa PR-10 protein β the major birch allergen (up to 95% of birch-allergic patients are IgE-positive per Moverare 2002) and the clinical target of birch SCIT. Bet v 2 is profilin, a pan-allergen found across the plant kingdom β it produces a broad, non-specific positive test to dozens of pollens and foods without reflecting true birch sensitization. Patients who are Bet v 2-dominant (profilin-positive, Bet v 1-negative) may test positive to whole birch extract but are unlikely to benefit from birch SCIT, because the allergen immunotherapy targets Bet v 1, not profilin. Component-resolved testing β available via blood test β distinguishes these two sensitization patterns and is arguably the most important pre-SCIT diagnostic step for birch.
Most patients report first noticeable improvement during the birch pollen season after completing 6β12 months of SCIT build-up. Because birch season spans only 6β8 weeks per year, it may take two full seasons to accurately assess benefit. The Bodtger 2002 and Arvidsson 2002 SCIT RCTs both demonstrated statistically significant symptom improvement within one to two birch seasons after reaching maintenance dose. Full immunologic tolerance β the lasting benefit that persists after stopping SCIT β typically requires completing the full 3β5 year course. Quitting in the first year substantially increases relapse risk.
It may, if your food reactions are PR-10-driven. Bet v 1 from birch pollen shares structural identity with Mal d 1 in apple, Cor a 1.04 in hazelnut kernel, and Pru p 1 in peach β so patients with birch-driven OAS often see improvement in these food reactions after successful birch SCIT. However, if your hazelnut or walnut kernel reaction is driven by storage proteins (heat-stable Cor a 9, Cor a 14, or Jug r 1/2/4), birch SCIT will not address those reactions and you will still need strict avoidance and an epinephrine auto-injector. A component-resolved allergy test is the only way to determine which category your food reactions fall into before making treatment decisions.
The strongest evidence for birch-allergen immunotherapy β the Itulazax TT-04 Phase 3 trial in 634 adults β actually used a SLIT tablet, not injections. This suggests the sublingual route can deliver clinically meaningful Bet v 1 immunotherapy. However, the Itulazax SLIT tablet is not FDA-approved in the US; off-label SLIT drops (non-standardized aqueous extract administered sublingually) are used clinically but lack the standardized dose and formal Phase 3 evidence of the EU tablet. Direct SCIT-vs-SLIT head-to-head trials specifically in birch are limited. Conventional SCIT injections remain the AAAAI/ACAAI guideline-endorsed first-line immunotherapy option for birch in the US.
There is evidence that allergen immunotherapy, including birch-targeted SCIT, may reduce the risk of new sensitizations and prevent allergic asthma progression β a concept supported by pediatric immunotherapy literature. The 2025 EU pediatric extension of Itulazax (based on the 952-child Phase 3) was supported in part on this preventive potential. However, these effects are probabilistic and not guaranteed. For patients with existing allergic asthma triggered by birch pollen, SCIT may reduce asthma exacerbation frequency during the spring season, but active, poorly controlled asthma should be stabilized before starting SCIT. A board-certified allergist should assess pulmonary function before initiating treatment. Once asthma is well-controlled, the injections themselves carry a strong safety record: a large safety study of self-administered allergen immunotherapy (Schaffer et al., 2015) found that across 23,614 patients giving 2,021,600 injections, the systemic reaction rate was just 0.16% per patient with no fatalities β lower than the 3%β14% typically seen with office-based shots.
Current AAAAI Practice Parameter guidance (Cox 2011; Greenhawt 2023) recommends against starting SCIT during pregnancy, because the build-up phase carries a small risk of systemic reactions that could harm the fetus. Patients who become pregnant while already in the maintenance phase of SCIT may often continue at their current maintenance dose, though the decision should be made in consultation with both the treating allergist and the obstetrics team. For newly pregnant patients seeking birch allergy relief during pregnancy, antihistamines that are considered safe in pregnancy (under OB guidance) and intranasal corticosteroids are the preferred options.
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.
Questions about Curex itself?
Straight answers about the company, the evidence, what patients report, and what it costs β including the parts that are not flattering.